Quinolones are a class of antibacterial agents for the treatment of several infectious diseases (e.g. urinary and respiratory tract infections). They are used worldwide due to their broad spectrum of activity, high bioavailability and good safety profile. The safety profile varies from quinolone to quinolone.
The aim of this article was to review the neurological and psychiatric adverse drug reaction (ADR) profile of quinolones, using a literature search strategy designed to identify case reports and case series. A literature search using PubMed/MEDLINE (from inception to 31 October 2010) was performed to identify case reports and case series related to quinolone-associated neurological and psychiatric ADRs. The search was conducted in two phases: the first phase was the literature search and in the second phase relevant articles were identified through review of the references of the selected articles. Relevant articles were defined as articles referring to adverse events/ reactions associated with the use of any quinolone. Abstracts referring to animal studies, clinical trials and observational studies were excluded. Identified case reports were analysed by age group, sex, active substances, dosage, concomitant medication, ambulatory or hospital-based event and seriousness, after Medical Dictionary for Regulatory Activities (MedDRA®) coding.
From a total of 828 articles, 83 were identified as referring to nervous system and/or psychiatric disorders induced by quinolones. 145 individual case reports were extracted from the 83 articles. 40.7% of the individual case reports belonged to psychiatric disorders only, whereas 46.9% related to neurological disorders only. Eight (5.5%) individual case reports presented both neurological and psychiatric ADRs. Ciprofloxacin, ofloxacin and pefloxacin were the quinolones with more neurological and psychiatric ADRs reported in the literature. Ciprofloxacin has been extensively used worldwide, which may explain the higher number of reports, while for ofloxacin and pefloxacin, the number of reports may be over-representative. A total of 232 ADRs were identified from the selected articles, with 206 of these related to psychiatric and/or neurological ADRs. The other 26 were related to other body systems but were reported together with the reactions of interest. Mania, insomnia, acute psychosis and delirium were the most frequently reported psychiatric adverse events; grand mal convulsion, confusional state, convulsions and myoclonus were the most frequently reported neurological adverse events.
Several aspects should be taken into account in the development of CNS adverse effects, such as the pharmacokinetics of quinolones, chemical structure and quinolone uptake in the brain. These events may affect not only susceptible patients but also ’healthy’ patients.
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
The authors would like to thank Liliana Coelho, assistant at the Medical Department, Grupo Tecnimede, for her support and assistance with retrieving full-text articles. Both authors are full-time employees of Grupo Tecnimede, which markets some fluoroquinolones (ciprofloxacin, levofloxacin, lomefloxacin and ofloxacin) in some European and non-European countries. No sources of funding were used to assist in the preparation of this review.
Dukes MNG, editor. Meyler’s side effects of drugs: the international encyclopedia of adverse drug reactions and interactions: fluoroquinolones. 15th ed. Amsterdam: Elsevier Science, 2006: 1396–407Google Scholar
Sprandel KA, Rodvold KA. Safety and tolerability of fluoroquinolones. Clin Cornerstone 2003; 5 Suppl. 3: S29–36CrossRefGoogle Scholar
Smith DA, Schmid EF. Drugs withdrawals and the lessons within. Curr Opin Drug Discov Devel 2006; 9(1): 38–46PubMedGoogle Scholar
Jo M, Tachi N, Shinoda M. Convulsions from excessive dosage of nalidixic acid: a case report. Brain Dev 1979; 1: 327–9PubMedCrossRefGoogle Scholar
Koppel C, Hopfe T, Menzel J. Central anticholinergic syndrome after ofloxacin overdose and therapeutic doses of diphenhydramine and chlormezanone. J Toxicol Clin Toxicol 1990; 28: 249–53PubMedCrossRefGoogle Scholar
Bagon JA. Neuropsychiatric complications following quinolone overdose in renal failure [letter]. Nephrol Dial Transpl 1999; 14: 1337CrossRefGoogle Scholar
Tattevin P, Messiaen T, Pras V, et al. Confusion and general seizures following ciprofloxacin administration. Nephrol Dial Transplant 1998; 13: 2712–3PubMedCrossRefGoogle Scholar
Aoun M, Jacquy C, Debusscher L, et al. Peripheral neuropathy associated with fluoroquinolones [letter]. Lancet 1992; 340: 127PubMedCrossRefGoogle Scholar
Orón JD, Ivorra J, Portilla J, et al. Reacción psicótica tras la administración de indometacina y ciprofloxacino [letter]. Rev Clin Esp 1992; 191: 401PubMedGoogle Scholar
Altés J, Gascó J, Antonio J, et al. Ciprofloxacin and delirium. Ann Intern Med 1989; 110: 170–1PubMedGoogle Scholar
McDermott JL, Gideonse N, Campbell JW. Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient. J Am Geriatr Soc 1991; 39: 909–10PubMedGoogle Scholar
Tamai I, Yamashita J, Kido Y, et al. Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier. J Pharmacol Exp Ther 2000; 295(1): 146–52PubMedGoogle Scholar
Mandell L, Tillotson G. Safety of fluoroquinolones: an update. Can J Infect Dis 2002; 13(1): 54–61PubMedGoogle Scholar
Spivey JM, Laughlin PH, Goss TF, et al. Theophylline toxicity secondary to ciprofloxacin administration. Ann Emerg Med 1991; 20: 1131–4PubMedCrossRefGoogle Scholar
Herrlin K, Segerdahl M, Gustafsson LL, et al. Methadone, ciprofloxacin, and adverse drug reactions. Lancet 2000; 356: 2069–70PubMedCrossRefGoogle Scholar
Fan-Havard P, Sanchorawala V, Oh J, et al. Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures. Ann Pharmacother 1994; 28: 869–72Google Scholar
Rollof J, Vinge E. Neurological adverse effects during concomitant treatment with ciprofloxacin, NSAIDs, and chloroquine: possible drug interaction. Ann Pharmacother 1993; 27: 1058–9PubMedGoogle Scholar
Lee J, Franz L, Goforth HW. Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine [letter]. Psychosomatics 2009; 50(6): 638–9PubMedGoogle Scholar
Sharma DD, Aggarwal A, Sharma RC, et al. A probable association of acute dystonia with gemifloxacin administration. Indian J Med Sci 2009; 63(12): 557–60PubMedCrossRefGoogle Scholar
Christie MJ, Wong K, Ting RH, et al. Generalized seizure and toxic epidermal necrolysis following levofloxacin exposure. Ann Pharmacother 2005; 39(5): 953–5PubMedCrossRefGoogle Scholar
Romano C, Cristina T, Daniela C, et al. Epileptic attacks associated with pefloxacin treatment in a patient on CAPD [letter]. Clin Nephrol 1989; 32: 48–9PubMedGoogle Scholar
Bercault N, DeMasure M, Benhamou CL, et al. Seizures in the course of prolonged treatment with ofloxacin. Rev Med Interne 1993; 14: 194PubMedCrossRefGoogle Scholar
Slavich IL, Gleffe RF, Haas EJ. Grand mal epileptic seizures during ciprofloxacin therapy. JAMA 1989; 261: 558–9PubMedCrossRefGoogle Scholar
Karki SD, Bentley DW, Raghavan M. Seizure with ciprofloxacin and theophylline combined therapy. DICP 1990; 24(6): 595–6PubMedGoogle Scholar
Semel JD, Allen N. Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole. South Med J 1991; 84: 465–8PubMedCrossRefGoogle Scholar
Abouesh A, Stone C, Hobbs WR. Antimicrobial-induced mania (antibiomania): a review of spontaneous reports. J Clin Psychopharmacol 2002; 22: 71–81PubMedCrossRefGoogle Scholar
Lucet JC, Tilly J, Lerebours G, et al. Neurological toxicity related to pefloxacin [letter]. J Antimicrob Chemother 1988; 21: 811–2PubMedCrossRefGoogle Scholar
Walton GD, Hon JK, Mulpur TG. Ofloxacin-induced seizures. Ann Pharmacother 1997; 31(12): 1475–7PubMedGoogle Scholar
Jeandel C, Laurain MC, Jouanny P, et al. État de mal épileptique sous ofloxacine. Rev Med Interne 1994; 15: 218–9PubMedCrossRefGoogle Scholar
Leone R, Venegoni M, Motola D, et al. Adverse drug reactions related to the use of fluoroquinolone anti-microbials: an analysis of spontaneous reports and fluor-oquinolone consumption data from three Italian regions. Drug Saf 2003; 26(2): 109–20PubMedCrossRefGoogle Scholar
Halliwell RF, Su J, Demuro A, et al. Characterization of the interaction between a novel convulsant agent, norbiphen, and GABAA and other ligand-gated ion channels. Neuropharmacology 2002; 43: 778–87PubMedCrossRefGoogle Scholar
Shimada J, Hori S. Adverse effects of fluoroquinolones. Prog Drug Res 1992; 38: 133–43PubMedGoogle Scholar
Kim J, Ohtani H, Tsujimoto M, et al. Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal anti-inflammatory agents. Drug Metab Pharmacokinet 2009; 24(2): 167–74PubMedCrossRefGoogle Scholar
Marinella MA. Myoclonus and generalized seizures associated with gatifloxacin treatment. Arch Intern Med 2001; 161: 2261–2PubMedCrossRefGoogle Scholar
Lahmek P, Michel L, Meunier N, et al. A seizure attributed to ofloxacine in a woman undergoing detoxification for alcohol dependence. Case Report Med. Epub 2010 Jan 24Google Scholar
Agbaht K, Bitik B, Piskinpasa S, et al. Ciprofloxacin-associated seizures in a patient with underlying thyrotoxicosis: case report and literature review. Int J Clin Pharmacol Ther 2009; 47(5): 303–10PubMedGoogle Scholar
Hall CE, Keegan H, Rogstad KE. Psychiatric side effects of ofloxacin used in the treatment of pelvic inflammatory disease. Int J STD AIDS 2003; 14(9): 636–7PubMedCrossRefGoogle Scholar
McCue JD, Zandt JR. Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole. Am J Med 1991; 90(4): 528–9PubMedCrossRefGoogle Scholar
Grimm O, Alm B, Fur Seelische Z. A case of ciprofloxacin-induced acute polymorphic psychosis with a distinct deficit in executive functions [letter]. Psychosomatics 2007; 48(3): 269PubMedCrossRefGoogle Scholar
Norra C, Skobel E, Breuer C, et al. Ciprofloxacin-induced acute psychosis in a patient with multidrug-resistant tuberculosis. Eur Psychiatry 2003; 18(5): 262–3PubMedCrossRefGoogle Scholar
Farrington J, Stoudemire A, Tierney J. The role of ciprofloxacin in a patient with delirium due to multiple etiologies. Gen Hosp Psychiatry 1995; 17: 47–53PubMedCrossRefGoogle Scholar
Ahuja N, Lloyd AJ. Antibiomania and ciprofloxacin-induced mania [letter]. Psychosomatics 2007; 48(4): 36CrossRefGoogle Scholar
de Bazignan AD, Thiessard F, Miremont-Salamé G, et al. Psychiatric adverse effects of fluoroquinolones: review of cases from the French pharmacologic surveillance database. Rev Med Interne 2006; 27(6): 448–52CrossRefGoogle Scholar
Steinert T, Studemund H. Acute delusional parasitosis under treatment with ciprofloxacin. Pharmacopsychiatry 2006; 39(4): 159–60PubMedCrossRefGoogle Scholar